Abstract:The market for biotherapeutic monoclonal antibodies (mAbs) is large and is growing rapidly. However, attrition poses a significant challenge for the development of mAbs, and for biopharmaceuticals in general, with large associated costs in resource and animal use. Termination of candidate mAbs may occur due to poor translation from preclinical models to human safety. It is critical that the industry addresses this problem to maintain productivity. Though attrition poses a significant challenge for pharmaceuticals in general, there are specific challenges related to the development of antibody-based products. Due to species specificity, non-human primates (NHP) are frequently the only pharmacologically relevant species for nonclinical safety and toxicology testing for the majority of antibody-based products, and therefore, as more mAbs are developed, increased NHP use is anticipated. The integration of new and emerging in vitro and in silico technologies, e.g., cell- and tissue-based approaches, systems pharmacology and modeling, have the potential to improve the human safety prediction and the therapeutic mAb development process, while reducing and refining animal use simultaneously. In 2014, to engage in open discussion about the challenges and opportunities for the future of mAb development, a workshop was held with over 60 regulators and experts in drug development, mechanistic toxicology and emerging technologies to discuss this issue. The workshop used industry case-studies to discuss the value of the in vivo studies and identify opportunities for in vitro technologies in human safety assessment. From these and continuing discussions it is clear that there are opportunities to improve safety assessment in mAb development using non-animal technologies, potentially reducing future attrition, and there is a shared desire to reduce animal use through minimised study design and reduced numbers of studies.

New Horizons in Therapeutic Antibody Discovery: Opportunities and Challenges versus Small-Molecule Therapeutics

Antibody Conjugates-Recent Advances and Future Innovations

Next generation antibody drugs: pursuit of the 'high-hanging fruit'

The role of therapeutic antibodies in drug discovery

Discovery of Therapeutic Antibodies Targeting Complex Multi-Spanning Membrane Proteins

The Dawn of a New Era: Targeting the "Undruggables" with Antibody-Based Therapeutics.

Strategies and challenges for the next generation of antibody–drug conjugates

Polyreactivity and polyspecificity in therapeutic antibody development: risk factors for failure in preclinical and clinical development campaigns

The Current Landscape of Antibody-based Therapies in Solid Malignancies

The history of monoclonal antibody development – Progress, remaining challenges and future innovations

Therapeutic Monoclonal Antibodies to Complex Membrane Protein Targets: Antigen Generation and Antibody Discovery Strategies

Development of therapeutic antibodies for the treatment of diseases

Drug Development of Therapeutic Monoclonal Antibodies

Monoclonal antibodies: technologies for early discovery and engineering

Antibodies and associates: Partners in targeted drug delivery

Therapeutic Antibodies and Immunologic Conjugates

Building better monoclonal antibody-based therapeutics

Immunogenicity risk assessment and mitigation for engineered antibody and protein therapeutics

Bispecific Antibodies and Antibody–Drug Conjugates for Cancer Therapy: Technological Considerations

Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use

Comprehensive approaches to preclinical evaluation of monoclonal antibodies and their next-generation derivatives